We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Avacta Group Plc | LSE:AVCT | London | Ordinary Share | GB00BYYW9G87 | ORD 10P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.75 | -1.51% | 49.00 | 48.50 | 49.50 | 49.75 | 49.00 | 49.75 | 201,919 | 08:18:46 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 10.06M | -39.19M | -0.1382 | -3.60 | 141.1M |
From Apr 2019 to Apr 2024
TIDMAVCT
RNS Number : 7719Z
Avacta Group PLC
05 September 2018
5 September 2018
Avacta Group plc
("Avacta", the "Group" or the "Company")
Notice of Results
Avacta Group plc (AIM: AVCT), the developer of Affimer(R) biotherapeutics and reagents, will announce its financial results for the year ended 31 July 2018 on Tuesday, 2 October 2018.
An analyst briefing given by Alastair Smith, Chief Executive Officer and Tony Gardiner, Chief Financial Officer, will be held at 09.30 hrs on Tuesday, 2 October 2018 at finnCap's offices, 60 New Broad St, London EC2M 1JJ.
- Ends -
For further information from Avacta Group plc, please contact:
Hot Features
Premium
Avacta Group plc Tel: +44 (0) 844 414 0452
Alastair Smith, Chief Executive Officer www.avacta.com
Tony Gardiner, Chief Financial Officer
finnCap Ltd Tel: +44 (0) 207 220 0500
Geoff Nash / Giles Rolls - Nominated www.finncap.com
Adviser
Tim Redfern / Nikita Jain - Corporate
Broking Tel: +44 (0) 203 705 9318
Tel: +44 (0) 203 705 9317
WG Partners www.wgpartners.co.uk
Nigel Birks / Nigel Barnes
David Wilson / Claes Spang
Zyme Communications (Trade and Regional Tel: +44 (0)7787 502 947
Media) katie.odgaard@zymecommunications.com
Katie Odgaard
Tel: +44 (0)7764 947137
Yellow Jersey (Financial Media and avacta@yellowjerseypr.com
IR)
Sarah Hollins
About Avacta Group plc (www.avacta.com)
Avacta's principal focus is on its proprietary Affimer(R) technology which is a novel engineered alternative to antibodies that has wide application in Life Sciences for diagnostics, therapeutics and general research and development.
Antibodies dominate markets worth in excess of $100bn despite their shortcomings. Affimer technology has been designed to address many of these negative performance issues, principally; the time taken to generate new antibodies, the reliance on an animal's immune response, poor specificity in many cases, and batch to batch variability. Affimer technology is based on a small protein that can be quickly generated to bind with high specificity and affinity to a wide range of protein targets.
Avacta has a pre-clinical biotech development programme with an in-house focus on immuno-oncology and bleeding disorders as well as partnered development programmes. Avacta is commercialising non-therapeutic Affimer reagents through licensing to developers of life sciences research tools and diagnostics.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
NORSSEESLFASESU
(END) Dow Jones Newswires
September 05, 2018 02:01 ET (06:01 GMT)
1 Year Avacta Chart |
1 Month Avacta Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
